Efalizumab-induced bullous pemphigoid

Journal of the American Academy of Dermatology

Volumn 62, Issue 1, 2010, Pages 161-162

  Duong, Tu Anh ^a   Buffard, Valérie ^a   André, Chantal ^a   Ortonne, Nicolas ^a   Revuz, Jean ^a   Bagot, Martine ^a   Roujeau, Jean Claude ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; COMPLEMENT COMPONENT C3; CORTICOSTEROID; EFALIZUMAB; ETRETIN; IMMUNOGLOBULIN G; METICILLIN; PSORALEN;

ADULT; ANTIBODY TITER; ANTIGENICITY; ARTICLE; BULLOUS PEMPHIGOID; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOFLUORESCENCE TEST; MALE; PRIORITY JOURNAL; PSORIASIS; ULTRAVIOLET A RADIATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PEMPHIGOID, BULLOUS; PSORIASIS;

EID: 71649109688     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.02.031     Document Type: Article

References (5)

1. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 5 (2006) 197-209
2. Wilczek A., and Sticherling M. Concomitant psoriasis and bullous pemphigoid: coincidence or pathogenic relationship?. Int J Dermatol 45 (2006) 1353-1357
3. Leonardi C., Menter A., Hamilton T., Caro I., Xing B., and Gottlieb A.B. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 158 (2008) 1107-1116
4. Kwan J.M., Reese A.M., and Trafeli J.P. Delayed autoimmune hemolytic anemia in efalizumab-treated psoriasis. J Am Acad Dermatol 58 (2008) 1053-1055
5. Adis International. Efalizumab: progressive multifocal leukoencephalopathy (first case) in an elderly patient: case report. Reactions 1223 (2008) 10